Search research articles
Contact Us
Filters
Showing results (111-120 of 236) with videos related to
Page
of 24
Sort By:
The Journal of Experimental Medicine
|
January 25, 2017
The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment
Jason B Williams, Brendan L Horton, Yan Zheng, et al.
Cancer Research
|
February 12, 2004
PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells
Christian Blank, Ian Brown, Amy C Peterson, et al.
Journal of Translational Medicine
|
May 30, 2012
Workshop on immunotherapy combinations. Society for Immunotherapy of Cancer annual meeting Bethesda, November 3, 2011
Ivan Martinez Forero, Hideho Okada, Suzanne L Topalian, et al.
Cancer Immunology Research
|
January 8, 2026
Phase II trial of interleukin-12 followed by interferon alfa-2b in patients with metastatic malignant melanoma: Results from CALGB 500001 (Alliance)
Alvin Liu, Courtney Johnson, Donna Niedzwiecki, et al.
Molecular Immunology
|
April 4, 2013
Egr2-dependent gene expression profiling and ChIP-Seq reveal novel biologic targets in T cell anergy
Yan Zheng, Yuanyuan Zha, Robbert M Spaapen, et al.
The Journal of Biological Chemistry
|
February 13, 2003
Gene array and protein expression profiles suggest post-transcriptional regulation during CD8+ T cell differentiation
Candace M Cham, Hui Xu, James P O'Keefe, et al.
Journal for Immunotherapy of Cancer
|
March 15, 2020
A case of dual-mechanism immune-related anaemia in a patient with metastatic melanoma treated with nivolumab and ipilimumab
Daniel J Olson, Padma Rajagopal, Melissa Y Tjota, et al.
Science Translational Medicine
|
August 30, 2013
Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells
Stefani Spranger, Robbert M Spaapen, Yuanyuan Zha, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 10, 2005
Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma
Thomas F Gajewski, Jeffrey Sosman, Stanton L Gerson, et al.
The Journal of Clinical Investigation
|
April 27, 2013
CD40 ligation reverses T cell tolerance in acute myeloid leukemia
Long Zhang, Xiufen Chen, Xiao Liu, et al.
Page
of 24
Search research articles
Search
Showing results (111-120 of 236) with videos related to
Sort By:
Page
of 24
The Journal of Experimental Medicine
|
January 25, 2017
The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment
Jason B Williams, Brendan L Horton, Yan Zheng, et al.
Cancer Research
|
February 12, 2004
PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells
Christian Blank, Ian Brown, Amy C Peterson, et al.
Journal of Translational Medicine
|
May 30, 2012
Workshop on immunotherapy combinations. Society for Immunotherapy of Cancer annual meeting Bethesda, November 3, 2011
Ivan Martinez Forero, Hideho Okada, Suzanne L Topalian, et al.
Cancer Immunology Research
|
January 8, 2026
Phase II trial of interleukin-12 followed by interferon alfa-2b in patients with metastatic malignant melanoma: Results from CALGB 500001 (Alliance)
Alvin Liu, Courtney Johnson, Donna Niedzwiecki, et al.
Molecular Immunology
|
April 4, 2013
Egr2-dependent gene expression profiling and ChIP-Seq reveal novel biologic targets in T cell anergy
Yan Zheng, Yuanyuan Zha, Robbert M Spaapen, et al.
The Journal of Biological Chemistry
|
February 13, 2003
Gene array and protein expression profiles suggest post-transcriptional regulation during CD8+ T cell differentiation
Candace M Cham, Hui Xu, James P O'Keefe, et al.
Journal for Immunotherapy of Cancer
|
March 15, 2020
A case of dual-mechanism immune-related anaemia in a patient with metastatic melanoma treated with nivolumab and ipilimumab
Daniel J Olson, Padma Rajagopal, Melissa Y Tjota, et al.
Science Translational Medicine
|
August 30, 2013
Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells
Stefani Spranger, Robbert M Spaapen, Yuanyuan Zha, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 10, 2005
Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma
Thomas F Gajewski, Jeffrey Sosman, Stanton L Gerson, et al.
The Journal of Clinical Investigation
|
April 27, 2013
CD40 ligation reverses T cell tolerance in acute myeloid leukemia
Long Zhang, Xiufen Chen, Xiao Liu, et al.
Page
of 24